Laura Maggino
University of Verona
Survival analysisInternal medicineRadiologySurgeryOncologyRetrospective cohort studyPathologicalSurvival rateFOLFIRINOXCarcinomaNeoadjuvant therapyPancreatectomyPancreasPancreaticoduodenectomyPancreatic cancerLymph nodePancreatic fistulaAdenocarcinomaPancreatic ductal adenocarcinomaDistal pancreatectomyGeneral surgeryMedicineCohortGastroenterology
73Publications
14H-index
755Citations
Publications 68
Newest
#1Laura Maggino (University of Verona)H-Index: 14
#2Andrea SchmidtH-Index: 1
Last. Sébastien GaujouxH-Index: 42
view all 13 authors...
: MINI: The characteristics of cystic pancreatic neuroendocrine neoplasms (cPanNENs) are largely unknown, and their clinical management remains unclear; specifically, an observational strategy for asymptomatic cPanNENs ≤2 cm has been proposed by recent guidelines, but evidence is scarce and limited to single institutional series. In this international cohort study of 263 resected cPanNENs from 16 institutions worldwide, a preoperative size >2 cm was independently associated with aggressive behav...
2 CitationsSource
#1Fabio Casciani (UPenn: University of Pennsylvania)H-Index: 2
#2Maxwell T. Trudeau (UPenn: University of Pennsylvania)H-Index: 3
Last. Ronald R. SalemH-Index: 29
view all 55 authors...
Abstract Background The association between intraoperative estimated blood loss and outcomes after pancreatoduodenectomy has, thus far, been rarely explored. Methods In total, 7,706 pancreatoduodenectomies performed at 18 international institutions composing the Pancreas Fistula Study Group were examined (2003–2020). High estimated blood loss (>700 mL) was defined as twice the median. Propensity score matching (1:1 exact-match) was employed to adjust for variables associated with high estimated ...
Source
#1Fabio Casciani (UPenn: University of Pennsylvania)H-Index: 2
#2Maxwell T. Trudeau (UPenn: University of Pennsylvania)H-Index: 3
Last. John W. KunstmanH-Index: 18
view all 55 authors...
Abstract Background Pancreatoduodenectomies at high risk for clinically relevant pancreatic fistula are uncommon, yet intimidating, situations. In such scenarios, the impact of individual surgeon experience on outcomes is poorly understood. Methods The fistula risk score was applied to identify high-risk patients (fistula risk score 7–10) from 7,706 pancreatoduodenectomies performed at 18 international institutions (2003–2020). For each case, surgeon pancreatoduodenectomy career volume and years...
3 CitationsSource
#1Thomas HankH-Index: 11
#2Ulf HinzH-Index: 64
Last. Oliver StrobelH-Index: 50
view all 15 authors...
Objective To develop and validate a pretreatment prognostic score in pancreatic cancer (PDAC). Background Pretreatment prognostication in PDAC is important for treatment decisions but remains challenging. Available prognostic tools are derived from selected cohorts of patients who underwent resection, excluding up to 20% of patients with exploration only, and do not adequately reflect the pretreatment scenario. Methods Patients undergoing surgery for PDAC in Heidelberg from 07/2006 to 06/2014 we...
1 CitationsSource
#1Giuseppe Malleo (University of Verona)H-Index: 43
#2Roberto Salvia (University of Verona)H-Index: 52
Last. Giovanni Butturini (University of Verona)H-Index: 51
view all 13 authors...
BACKGROUND Pancreatic metastases (PM) from renal cell carcinoma (RCC) are uncommon. We herein describe the long-term outcomes associated with pancreatectomy at two academic institutions, with a specific focus on 10-year survival. METHODS This investigation was limited to patients undergoing pancreatectomy for PM between 2000 and 2008 at the University of Verona and Memorial Sloan Kettering Cancer Center, allowing a potential for 10 years of surveillance. The probabilities of further RCC recurren...
2 CitationsSource
#1Fabio CascianiH-Index: 5
#2Raffaele De LucaH-Index: 11
Last. Giuseppe MalleoH-Index: 43
view all 9 authors...
Source
#1Savio G. Barreto (Flinders University)H-Index: 22
#1Savio G Barreto (Flinders University)H-Index: 2
Last. John A. Windsor (Auckland City Hospital)H-Index: 71
view all 12 authors...
Abstract Background Health care expenditure is increasing around the world and surgery is a major cause of financial hardship to patients and their families. Using pancreatoduodenectomy (PD), one of the most complex, morbid and costly operation as an example, this study aimed to identify the cost drivers of surgery, estimate relative contribution of these drivers, and derive and validate a cohort-specific cost forecasting tool. Methods Data on the costs of 1406 patients undergoing PD in three te...
Source
#1Giuseppe Malleo (University of Verona)H-Index: 43
#2Laura Maggino (University of Verona)H-Index: 14
Last. Roberto Salvia (University of Verona)H-Index: 52
view all 14 authors...
OBJECTIVE To reappraise the optimal number of examined lymph nodes (ELN) in pancreatoduodenectomy (PD) for pancreatic ductal adenocarcinoma (PDAC). SUMMARY BACKGROUND DATA The well-established threshold of 15 ELN in PD for PDAC is optimized for detecting one positive node (PLN) per the previous 7 edition of the AJCC staging manual. In the framework of the 8 edition, where at least four PLN are needed for an N2 diagnosis, this threshold may be inadequate for accurate staging. METHODS Patients who...
Source
#1Maximilian Weniger (LMU: Ludwig Maximilian University of Munich)H-Index: 11
#2John Moir (Freeman Hospital)H-Index: 6
Last. Richard Charnley (Freeman Hospital)H-Index: 29
view all 8 authors...
Abstract Introduction The number of people aged 60 and above will rise from 46 million in 2015 to 157 in 2050 million, exceeding 30% of the population in many western countries. Consequently, the demand for oncological therapy for elderly patients will increase within the next decades. Currently, sufficient data on neoadjuvant therapy (NTx) of pancreatic cancer in elderly patients are lacking. Methods Data of a multinational, retrospective database were screened for patients having received preo...
1 CitationsSource
#1Maximilian Weniger (LMU: Ludwig Maximilian University of Munich)H-Index: 11
#2John Moir (Freeman Hospital)H-Index: 6
Last. Patrick MichlH-Index: 15
view all 30 authors...
Abstract Background Neoadjuvant chemotherapy has become a powerful tool to convert borderline resectable (BRPC) and locally advanced pancreatic cancers (LAPC) into a resectable scenario. However, data analyzing the optimal type of therapy are scarce. In the present multicenter retrospective study, we evaluated the influence of FOLFIRINOX (FFX) and gemcitabine (GEM)-based neoadjuvant therapy on patient prognosis. Methods Data on 239 patients from 7 centers across Europe was gathered using an onli...
6 CitationsSource